Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8324037 | 0.82 | NAAA (0.74) | NAAAFAAHPOLB | |
| SCHEMBL16193763 | 0.77 | POLB (0.78) | NAAAFAAHALDH1A1MAPTPOLB | |
| SCHEMBL16335626 | 0.76 | FAAH (0.61) | NAAAFAAHALDH1A1MAPTTSHR | |
| SCHEMBL8778553 | 0.71 | HPGD (0.51) | NAAAFAAHALDH1A1CYP1A2MAPT | |
| SCHEMBL19612752 | 0.70 | NAAA (1.00) | NAAAFAAHKMT2A | |
| SCHEMBL5015512 | 0.70 | POLB (0.77) | NAAAALDH1A1MAPTPOLBHPGD | |
| SCHEMBL19628792 | 0.70 | NAAA (1.00) | NAAAFAAHKMT2AHPGD | |
| SCHEMBL8778482 | 0.70 | HPGD (0.54) | NAAAFAAHALDH1A1MAPTKMT2A | |
| SCHEMBL30063016 | 0.70 | ALDH1A1 (0.55) | NAAAFAAHALDH1A1CYP1A2MAPT | |
| SCHEMBL2685197 | 0.69 | ALDH1A1 (1.00) | ALDH1A1CYP1A2MAPTCYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598383-B2 | Reactive oxygen species-based prodrugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150005352-A1 | REACTIVE OXYGEN SPECIES-BASED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005352-A1 | REACTIVE OXYGEN SPECIES-BASED PRODRUGS | ROS1, NOX4, NOX1 | NAAA 2323/4885FAAH 4085/4885ALDH1A1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.